Ascletis Announces ASC47, a Muscle-Preserving Weight Loss Drug Candidate for Treatment of Obesity, in Combination with Semaglutide, Demonstrated Superior Weight Loss to Semaglutide Monotherapy in a Preclinical Model
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 18 2024
0mins
Source: PRnewswire
Efficacy of ASC47 in Weight Loss: A study on diet-induced obese mice showed that a low dose combination of ASC47 and semaglutide resulted in a 36.2% weight loss, significantly outperforming semaglutide alone, which achieved only 23.1% weight loss.
Safety and Tolerability: Interim data from a Phase I study indicated that ASC47 was well tolerated at doses up to 90 mg with no serious adverse events, while also demonstrating improvements in body composition and reductions in liver enzymes compared to vehicle treatment.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
